检索范围:
排序: 展示方式:
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
《医学前沿(英文)》 2021年 第15卷 第2期 页码 221-231 doi: 10.1007/s11684-020-0812-7
关键词: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Multi-target combinatory strategy to overcome tumor immune escape
《医学前沿(英文)》 2022年 第16卷 第2期 页码 208-215 doi: 10.1007/s11684-022-0922-5
关键词: immune checkpoints multi-target immune escape immune-related adverse events combination therapy
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
《医学前沿(英文)》 2009年 第3卷 第3期 页码 256-264 doi: 10.1007/s11684-009-0052-3
关键词: target therapy gynecologic malignant tumors clinical trail molecular medicine
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 52-60 doi: 10.1007/s11684-016-0433-3
Hepatocellular carcinoma (HCC) is a lethal liver malignancy worldwide. In this study, we reported that protein phosphatase magnesium-dependent 1δ (PPM1D) was highly expressed in the majority of HCC cases (approximately 59%) and significantly associated with high serum α-fetoprotein (AFP) level (P= 0.044). Kaplan-Meier and Cox regression data indicated that PPM1D overexpression was an independent predictor of HCC-specific overall survival (HR, 2.799; 95% CI, 1.346–5.818, P = 0.006). Overexpressing PPM1D promoted cell viability and invasion, whereas RNA interference-mediated knockdown of PPM1D inhibited proliferation, invasion, and migration of cultured HCC cells. In addition, PPM1D suppression by small interfering RNA decreased the tumorigenicity of HCC cells in vivo. Overall, results suggest that PPM1D is a potential prognostic marker and therapeutic target for HCC.
关键词: PPM1D hepatocellular carcinoma prognosis target therapy
Probes and nano-delivery systems targeting NAD(P)H:quinone oxidoreductase 1: a mini-review
《化学科学与工程前沿(英文)》 2023年 第17卷 第2期 页码 123-138 doi: 10.1007/s11705-022-2194-7
关键词: NAD(P)H:quinone oxidoreductase 1 cancer therapy target probe nanosystem
《医学前沿(英文)》 2022年 第16卷 第5期 页码 784-798 doi: 10.1007/s11684-021-0911-0
关键词: uveal melanoma mutant GNAQ/11 palmitoylation BCL2 combination target therapy
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Particle therapy for cancers: a new weapon in radiation therapy
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 165-172 doi: 10.1007/s11684-012-0196-4
Particle irradiation started to draw attention in the past decade and has now become a hotspot in the radiation oncology community. This article reviews the most advanced developments in particle irradiation, focusing on the characteristics of proton and carbon ions in radiation physics and radiobiology. The Bragg peak of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancer irradiation because the Bragg peak permits the accurate concentration of the dose on the tumor, thus sparing the adjacent normal tissues. Moreover, carbon ion has more radiobiological benefits than photon and proton beams. These benefits include stronger sterilization effects on intrinsic radio-resistant tumors and more effective killing of hypoxic, G0, and S phase cells. Compared with the most advanced radiation techniques using photon, such as three-dimensional conformal radiation therapy and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in local control and survival for head and neck cancers, prostate carcinoma, and pediatric cancers. Carbon therapy in Japan showed even more promising results than proton therapy. The local controls and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancer, hepatocellular carcinoma, prostate carcinoma, and head and neck cancers, especially for such highly resistant tumors as melanoma. The non-invasive nature of particle therapy affords more patients with chances to receive and benefit from treatment. Particle therapy is gradually getting attention from the oncology community. However, the cost of particle therapy facilities has limited the worldwide use of this technology.
关键词: radiation therapy particle therapy proton carbon cancer
Atypical pituitary hormone–target tissue axis
《医学前沿(英文)》 2023年 第17卷 第1期 页码 1-17 doi: 10.1007/s11684-022-0973-7
关键词: thyroid-stimulating hormone follicle-stimulating hormone luteinizing hormone adrenocorticotrophic hormone prolactin
Passive antibody therapy in emerging infectious diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1021-y
关键词: SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
《医学前沿(英文)》 2019年 第13卷 第4期 页码 427-437 doi: 10.1007/s11684-018-0672-6
关键词: targeted therapy desmoid-type fibromatosis tyrosine kinase inhibitor γ-secretase inhibitor
Amodified variable rate particle filter for maneuvering target tracking
Yun-fei GUO,Kong-shuai FAN,Dong-liang PENG,Ji-an LUO,Han SHENTU
《信息与电子工程前沿(英文)》 2015年 第16卷 第11期 页码 985-994 doi: 10.1631/FITEE.1500149
关键词: Maneuvering target tracking Prolonged smooth regions Variable rate model Maneuver detection
Hydroxyl radical-involved cancer therapy via Fenton reactions
《化学科学与工程前沿(英文)》 2022年 第16卷 第3期 页码 345-363 doi: 10.1007/s11705-021-2077-3
关键词: hydroxyl radical Fenton catalyst hydrogen peroxide cancer therapy
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
Lightweight design of an electric bus body structure with analytical target cascading
《机械工程前沿(英文)》 2023年 第18卷 第1期 doi: 10.1007/s11465-022-0718-y
关键词: electric vehicle body in white (BIW) lightweight analytical target cascading (ATC)
标题 作者 时间 类型 操作
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
期刊论文
Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
期刊论文
Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma
null
期刊论文
Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma
期刊论文
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
期刊论文
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
期刊论文
Amodified variable rate particle filter for maneuvering target tracking
Yun-fei GUO,Kong-shuai FAN,Dong-liang PENG,Ji-an LUO,Han SHENTU
期刊论文